Compare Expedia Group Inc (EXPE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs TransMedics Group Inc — how do they compare? Expedia Group Inc trades at $326.02 (market cap $38.53B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Expedia Group Inc is far larger — about 12.4× TransMedics Group Inc's market cap, and Expedia Group Inc pays a 0.6% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| EXPE | TMDX | |
|---|---|---|
Market Cap | $38.53B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $321.07 | $150.42 |
52-Week Low | $188.51 | $61.99 |
Enterprise Value | $37.09B | $3.49B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $328.08, up 4.48% on the day, reflecting strong momentum after Q2 2026 earnings beat. The stock shows a bullish technical trend with moving averages aligned positively, while fundamentals highlight robust revenue growth, expanding margins, and consistent earnings outperformance. Recent news emphasizes AI integration and B2B growth driving upward guidance revisions.
Outlook remains favorable with raised full-year revenue guidance and solid cash flow generation, though elevated valuation multiples and overbought RSI levels near-term pose risks. Analyst consensus leans neutral with a $322.95 price target slightly below current levels, suggesting cautious optimism amid execution and competitive pressures.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
